Senior Director, Medical Director, Lung Cancer and Early Pipeline

The Senior Director, Medical Director, Lung Cancer and Early Pipeline will be the Medical Affairs lead for the lung cancer disease area and post proof of concept (POC) pipeline products, including early assets without a defined lead indication globally. They are a key member of Global Commercialization Organization Medical Affairs (GCOMA) Oncology and report to the Executive Director, Solid Tumor Lead.

The Senior Medical Director will be the subject matter expert lead for the Solid Tumor Oncology product, partnering closely with US cross-functional partners to create and execute the US Medical Affairs strategy, including the integrated evidence generation plan. This is a strategic role with execution responsibilities and is accountable for ensuring the needs and priorities of the US region are represented and addressed through engagement with key partners across Jazz. This role ensures a deep understanding of customer, patient, and healthcare system needs are represented consistently across cross-functional discussions and decision-making forums.

The Senior Medical Director will partner with the early/clinical development team to determine and align on future treatment landscape scenarios for assets in early development in additional therapeutic areas for early pipeline products without a lead indication and those in new oncology therapeutic areas. The Sr. Director will inform and influence clinical development strategy, evidence plans and the target product profile for such products, with a bias toward the United States therapeutic landscape as the driver of strategic planning.

The role serves as a critical interface between Medical Affairs and global R&D, Early/Clinical Development, Global Product Development and Commercialization functions, partnering closely with US colleagues to ensure regional insights and priorities are understood, communicated, and appropriately considered within the Global Product Team (GPT), Commercial Development Team (CDT), Medical Functional Matrix Team (FMT), and governance forums including the Portfolio Governance Committee (PGC) and Development Project Review Committee (DPRC).

Essential Functions/Responsibilities:

• Lead the Medical FMT for the Solid Tumor Oncology product
• Lead and develop the annual and long-range US Medical Plan for the Solid Tumor Oncology product
• Lead the development, maintenance, and execution of the Integrated Evidence Generation Plan (IEGP), including investigator-sponsored studies, real-world evidence initiatives, health outcomes research, and Phase IV interventional studies, where appropriate
• Lead the development of the scientific narrative for the Solid Tumor Oncology product by identifying and advancing key analytic needs and informing the interpretation of pivotal trial data
• Represent and advocate for medical perspectives within global cross-functional teams and governance forums, including GPT, CDT, PGC, and DPRC
• Contribute Medical Affairs expertise to inform early development activities for early pipeline assets, including Target Product Profile (TPP) development, clinical trial design and lifecycle planning based on regional insights and aligned future therapeutic landscape scenarios
• Ensure regional needs and insights are appropriately considered in early/clinical development discussions, evidence-generation activities, and lifecycle planning
• Ensures awareness and Medical Affairs functional alignment on early/clinical development programs
• Maintain and apply a deep understanding of the competitive landscape to inform evidence generation strategy and internal development decisions
• Partner effectively across Medical Affairs, Clinical Development, Regulatory Affairs, Market Access, HEOR, RWE, Commercial, and other cross-functional teams to support evidence generation and scientific exchange
• Lead development and execution of publication strategy and publication plans in alignment with regional evidence needs and scientific priorities
• Support scientific communications, congress planning, advisory boards, and external engagement activities as required

Required Knowledge, Skills, and Abilities

• A minimum of 10 years of Medical Affairs, Clinical Development, or related pharmaceutical or biotechnology industry experience is required, preferably in oncology
• Experience in Lung cancer therapies is strongly preferred
• Demonstrated experience developing and executing evidence-generation strategies, publication plans, and external scientific engagement activities
• Strong understanding of clinical research, evidence generation, and drug development
• Proven ability to influence without authority and operate effectively within complex matrix organizations
• Strong strategic thinking coupled with excellent operational execution skills
• Excellent written, verbal, presentation, and stakeholder management skills
• Ability to build productive partnerships across regions and functions and effectively represent diverse stakeholder perspectives
• Demonstrated ability to manage multiple priorities and deliver high-quality outcomes in a fast-paced environment
• Experience in lifecycle management of Lung cancer indications strongly desired
• Evidence of success in matrix organizations and track record of high performing behaviors, including independent critical thinking, initiative, and execution under time pressure with competing priorities
• Self-awareness and emotional intelligence as demonstrated by prior experience navigating complex matrix environments successfully

Required/Preferred Education and Licenses

• Advanced scientific or healthcare degree required (PharmD, PhD, MD, MBBS, Nurse Practitioner, PA, or equivalent)
• Experience in the delivery of oncology care preferred

#LI-Remote